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Studies using RNA interference in oocytes have elucidated processes relating to 
oocyte function and fertilization. Currently, the only viable method for genetic 
manipulation of oocytes is microinjection, a very time consuming procedure. There is no 
quantitative evidence of successful transfections with lipid-based vehicles in oocytes with 
the zona pellucida intact. Polycations are effective vehicles for delivering nucleic acids into 
mammalian cells, but have not been tested in oocytes. I investigated whether polycation-
mediated nucleic acid delivery is a feasible alternative to microinjection in oocytes. 
Polyethyleneimine (PEI) is a highly efficient polycationic vector that has been shown to 
deliver nucleic acids into a variety of cell types, including NIH 3T3 cells. PEI is commonly 
conjugated to polyethylene glycol (PEG) to reduce cytotoxicity and improve transfection 
efficiency. Commercial polycation-based nanoparticles, such as HappyFect, are also 
available for transfections in different cell types. As a functional assay to determine 
whether the polycations can be used as delivery agents in oocytes, I tested their ability to 
deliver siRNA that targets a specific gene called Ensa. I synthesized PEGylated PEI, 
characterized it using dynamic light scattering, and examined the ability of unmodified PEI 
and PEGylated PEI to complex with plasmid DNA or an RNA duplex using gel mobility 
shift assays. To assess the ability of PEI, PEGylated PEI and HappyFect to knockdown 
Ensa mRNA and ENSA protein in NIH 3T3 cells, I used an Ensa specific siRNA cocktail 
that was previously shown in the Evans Lab to knock down Ensa in oocytes via 
microinjection. Lipofectamine 2000 was used as a positive control, since it was shown to 
effectively knock down Ensa mRNA and ENSA protein in NIH 3T3 cells.  Since the 
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commercial polycation, HappyFect, was able to knock down Ensa transcript levels in NIH 
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1.1. Genetic Manipulation of Oocytes 
A greater understanding of biological processes in mammalian oocytes would 
have a tremendous impact on human reproductive health. In all areas of biomedical 
research, interfering with the function of gene products or deleting or reducing gene 
products is a fundamental approach for elucidating mechanisms underlying biological 
processes. Oocyte biology has benefited significantly from the development of RNA 
interference. RNAi has been a highly successful method of RNA ablation and subsequent 
protein knockdown in oocytes (Svoboda & Stein, 2009). 
The most commonly utilized method for delivering silencing RNAs (siRNAs) or 
short hairpin RNAs (shRNAs) into oocytes is microinjection. The microinjection of 
siRNA or shRNA requires significant skill and expensive equipment. Because 
microinjection is extremely time consuming and labor-intensive, the development of a 
time- and cost-effective alternative to microinjection would be highly beneficial for the 
field of oocyte biology. Such a method to introduce siRNAs or shRNAs would also make 
it possible to perform large-scale RNAi library screens with mammalian oocytes.  
1.2. Methods of Nucleic Acid Delivery  
There are multiple methods of delivering nucleic acids into cells. In general, 
nucleic acid delivery vehicles can be divided into two major categories: viral vectors and 
synthetic vectors. Each delivery method has specific advantages and disadvantages. 
Viruses have applications in gene therapy, as they can be transformed into gene-delivery 
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vehicles by replacing part of the genome of a virus with a therapeutic gene (Pack, 
Hoffman, Pun, & Stayton, 2005).  Synthetic vectors are materials that electrostatically 
bind DNA or RNA, condense the genetic material into particles a few tens to several 
hundred nanometers in diameter, and mediate cellular entry of the genetic material (Pack 
et al., 2005).  The majority of synthetic vectors can be further divided into 
polymers/polycations and lipids. As a result of their relatively high efficiency, lipid based 
delivery vehicles have been the most widely studied of the synthetic vectors (Zabner, 
1997). However, numerous synthetic polycations containing a variety of different 
chemical compositions have also been employed as vectors for nucleic acid delivery.  
1.3. Nucleic Acid Delivery in Oocytes 
 Ooctyes are female germ cells produced in the ovary during female 
gametogenesis. The egg coat of the mammalian egg is called the zona pellucida, and is 
important during fertilization for supporting the binding of sperm. During the growth of 
an oocyte, a variety of maternally transcribed mRNAs are recruited and translated into 
proteins that have various functions, from regulation of meiosis and cellular metabolism, 
to developmental processes like fertilization (Schultz, Letourneau, & Wassarman, 1979; 
Schultz & Wassarman, 1977). Meiosis in oocytes occurs in a staggered fashion; oocytes 
are arrested at prophase of meiosis I before birth and the arrest lasts for weeks to years, 
depending on the species.  Upon ovulation, oocytes undergo a transition known as 
meiotic maturation, during which oocytes exit from prophase I arrest and progress 
through meiosis I and then arrest at metaphase of meiosis II (Conti, Hsieh, Zamah, & Oh, 
2012).   Oocytes then complete meiosis II if they are fertilized.   
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Mouse oocytes and early embryos were the first mammalian tissues where RNAi 
was documented (Svoboda, Stein, Hayashi, & Schultz, 2000; Wianny & Zernicka-Goetz, 
2000). Microinjection is the most commonly utilized delivery method for RNAi in 
oocytes. Typically, oocytes that are arrested in prophase I are microinjected with shRNAs 
or siRNAs and then cultured for 24 + hours to allow RNAi-mediated knockdown and 
protein turnover to occur. Microinjection allows the introduction of siRNA or shRNA 
into zona pellucida (ZP)-intact oocytes at a defined concentration, and the timing of each 
experiment can be controlled stringently. While there are many advantages to this 
method, the technique requires comparatively expensive equipment and demands more 
time than many of the other methods used for other cell types. Electroporation is another 
method that has been used for the introduction of siRNA or shRNA into a large number 
of ZP-intact oocytes and embryos (Grabarek, Plusa, Glover, & Zernicka-Goetz, 2002), 
but conventional electroporation systems typically require expensive pulse generators 
(Geng, Zhan, & Lu, 2012).  
The use of synthetic vectors would circumvent the need for expensive equipment 
and reduce the amount of time required for performing RNAi experiments. There are 
only two reports of successful transfections in mammalian oocytes with lipid-based 
delivery agents. In one study, Lazar et al. transfected ZP-free rat oocytes that were 
arrested at prophase I with a dsRNA targeting Cyclin B1 mRNA using a commercial lipid 
transfection reagent, Lipofectamine (2004). Using RT-PCR, the authors showed that 
following a 2.5 hour incubation with Lipofectamine and the cyclin B1 dsRNA, cyclin B1 
mRNA was not detected in the ZP-free oocytes (Lazar, Gershon, & Dekel, 2004).  
Additionally, western blot analyses to quantify protein levels, showed that following a 
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12-hour incubation in the transfection mixture, full ablation of cyclin B1 protein was 
achieved in the ZP-free oocytes (Lazar et al., 2004).  
In another experiment, Carballada et al. transfected ZP-intact mouse oocytes 
arrested at prophase I with a rhodamine-labeled plasmid DNA using another commercial 
lipid vehicle, Fugene (2000). The authors determined whether ZP-intact oocytes were 
successfully transfected with the plasmid by visualizing rhodamine signals. After a 3-
hour transfection, they showed that out of 16 oocytes, all were positive for rhodamine 
labeling (Carballada, Degefa, & Esponda, 2000). As a control, four oocytes were 
transfected with Fugene alone, and none of these oocytes contained the rhodamine signal 
(Carballada et al., 2000).  However, the choice of transfecting control oocytes with 
Fugene alone seems questionable because it does not address whether it was the Fugene 
that delivered the plasmid to the oocytes or whether the rhodamine signals can be seen 
because of incomplete washes or the incorporation of the plasmid through some other 
mechanism. A more appropriate control would be treating the oocytes with the plasmid 
alone. Moreover, using fluorescence microscopy to examine transfection lacks 
quantitative evidence of the transfection efficiency of these lipid transfection agents in 
oocytes, and therefore raises questions about the capacity of lipids to transfect ZP-intact 
oocytes.  
Thus, while there is quantitative evidence of using lipid-based delivery vehicles to 
transfect ZP-free oocytes (Lazar et al., 2004), there is little to no quantitative evidence of 
using lipids to transfect ZP-intact oocytes. Furthermore, neither report addressed the 
toxicity of the lipid vectors. Toxicity can be a significant problem with some lipid based 
delivery agents. Gebhart & Kabanov demonstrated that the toxicity of lipolexes limits the 
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maximal dose of DNA that can be used in cell transfections; at higher doses of DNA, 
lipoplexes, made of a variety of commercially available lipid based delivery agents and a 
plasmid DNA, decreased cellular protein levels to a greater extent than poplypexes, made 
of a variety of different polycations and the same plasmid DNA (Gebhart & Kabanov, 
2001). 
In addition to cytotoxicity, lipid-based delivery agents have many other crucial 
limitations compared to polycations. The formation of lipoplexes involves interactions 
among lipid molecules, in addition to interactions with the DNA or RNA itself, but the 
self-assembly of polyplexes does not entail interactions of the polycation molecules with 
each other (Thomas & Klibanov, 2003). The lipids’ hydrophobic segments are the key 
determinants of the macroscopic characteristics of lipoplexes, such as their size, shape, 
stability, and interactions with other lipids, cell membranes, and DNA. This, in turn, 
affects the transfection efficiency of resulting lipoplexes (Smisterova et al., 2001; Zuhorn 
et al., 2002). While the ability to control these parameters in lipids is rather limited 
(Simberg et al., 2001), polycations consist of repeating structural units that can be easily 
manipulated by chemical modifications to achieve higher transfection efficiency. 
Another limitation of lipid delivery agents is that lipid based formulations often 
require adjuvant ‘helper lipids’ in order to facilitate the fusion of cationic liposomes to 
the cell membrane (Hui et al., 1996), but polycations are efficient without such adjuvants 
(Thomas & Klibanov, 2003). Finally, Gebhart and Kabanov also demonstrated that 
transfection efficiency using a variety of polycations is independent of the presence or 
absence of serum, while select lipid systems, according to manufacturer’s protocols, 
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should be used in the absence of serum (Gebhart & Kabanov, 2001). This in turn might 
allow for greater flexibility in some transfection conditions, such as incubation periods.  
To date, there is limited evidence of the use of lipid-based delivery agents and no 
evidence of the use of polycations, or nanoparticles, to transfect oocytes. However, the 
evidence of transfecting ZP-intact oocytes with lipid-based delivery agents is not 
quantitative and there is little known about the toxicity of lipid-based delivery agents in 
oocytes. Furthermore, it has been shown that toxicity is one among many limitations of 
lipid based delivery agents, as compared with polycations. Both the lack of quantitative 
evidence of lipid-based transfections in ZP-intact oocytes and the drawbacks of lipid 
delivery systems as compared with polycations, make polycations a compelling 
alternative to microinjection for the delivery of nucleic acids into ZP-intact oocytes.  
1.4. Polycation Mediated Delivery 
Polycations have linear, branched, or dendritic structures, and contain DNA-
binding moieties including primary, secondary, tertiary, and quaternary amines, as well 
as other positively charged groups, such as amidines (Pack et al., 2005).  Some 
commonly used polycations (Figure 1) include polylysine, polyethyleneimine, chitosan, 
and poly(-aminoesters). 
Delivery of nucleic acids into eukaryotic cells using polycations is a multi-step 
process that requires condensation of DNA or RNA with the polycation, cellular uptake 
via endocytosis/pinocytosis, and release from the endosome into the cytosol. Polycations 
interact electrostatically with the negatively charged phosphates of the DNA or RNA 
backbone and condense the genetic material into compact, ordered particles called 
polyplexes. Polyplexes are formulated according to their N/P ratio, which is the ratio of 
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the moles of nitrogen in the polycation to the moles of phosphate in the nucleic acid.  In 
most cases, the N/P ratio required for polyplex formation is determined empirically. At a 
certain critical N/P ratio, the nucleic acid undergoes localized bending or distortion that 
allows the formation polyplexes, which are typically toroidal or spherical structures 
(Hansma et al., 1998; Wagner, Cotten, Foisner, & Birnstiel, 1991) and range from 20-200 
nm in diameter (Dunlap, Maggi, Soria, & Monaco, 1997; Golan, Pietrasanta, Hsieh, & 
Hansma, 1999; Lynn, Anderson, Putnam, & Langer, 2001) 
Once formed, polyplexes can bind electrostatically to the surface of cells and are 
internalized via adsorptive pinocytosis (Mislick & Baldeschwieler, 1996). Alternatively, 
if the polyplexes contain targeting ligands, they can bind to specific cell-surface receptors 
and are internalized by receptor-mediated endocytosis. In either case, the polyplexes are 
localized within endocytic vesicles inside the cells. The first vesicle in which the 
polyplex is localized fuses with sorting endosomes from which the material can either be 
transported out of the cell by exocytosis, or into late endosomes, vesicles that are acidic 
(pH 5-6) due to ATPase proton pumps in the vesicle membrane. Polyplexes are then 
trafficked into lysosomes that contain various degradative enzymes. In order to deliver 
their nucleic acid cargo, polyplexes contained in the late endosomes must be able to 
escape into the cytoplasm before being degraded by endolysosomes.  
Several strategies have been developed to ensure that polyplexes are able to 
escape from late endosomes and evade lysosomal degradation.  Treating cells at the time 
of transfection with chloroquine, which buffers the pH of acidic vesicles, has been shown 
to promote endosomal escape and therefore improve transfection efficiency of some 
polymers (Erbacher, Roche, Monsigny, & Midoux, 1996).  Additionally, fusogenic 
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synthetic peptides, which undergo structural changes at acidic pH and disrupt vesicle 
membranes, have been attached to polymers in order to promote endosomal escape (Lee, 
Jeong, & Park, 2001; Vaysse, Burgelin, Merlio, & Arveiler, 2000; Wyman et al., 1997). 
Finally, some polymers, such as polyethyleneimine (PEI) and polyamidoamine 
(PAMAM) dendrimers, are thought to mediate their own endosomal escape through a 
mechanism known as the ‘proton sponge effect’ (Boussif et al., 1995). 
1.5. Polyethyleneimine and the Proton Sponge Effect 
Polyethyleneimine is one of the most effective gene-delivery polymers and has 
been shown to efficiently deliver nucleic acids into a variety of different mammalian cells 
in culture (Boussif et al., 1995). The relatively high nucleic acid delivery efficiency of 
PEI is believed to be due primarily to the efficient escape of polyplexes from the 
endocytic pathway.  PEI is an organic macromolecule that can exist in a linear or 
branched form. It is available in a broad range of molecular weights.  The molecular 
weight of PEI most suitable for gene transfer ranges between 5 and 25 kD (Neu, Fischer, 
& Kissel, 2005).  Higher molecular weight PEI tends to be more cytotoxic (Fischer, Li, 
Ahlemeyer, Krieglstein, & Kissel, 2003) due to aggregation of clusters of the polymer 
that induces necrosis (Fischer, Bieber, Li, Elsasser, & Kissel, 1999). 
Because PEI is rich in secondary and tertiary amines, it is readily protonated in 
the acidic environment of the endosome, and consequently has a very high cationic 
charge density potential (Boussif et al., 1995). Thus, PEI polyplexes act as proton 
sponges inside the endosome, resulting in an influx of protons that stimulates the entrance 
of water from the cytosol to balance the high osmotic pressure. The subsequent swelling 
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eventually leads to the rupture of the endosome and release of the PEI polyplexes into the 
cytosol.  
PEI has been used as a delivery vehicle in a variety of different mammalian cell 
lines, including NIH 3T3 murine fibroblasts, COS-7 monkey kidney, HepG2 human 
hepatoma, HeLa human epithelial carcinoma, and many more (Boussif et al., 1995). 
Although PEI-mediated transfections have been shown to be particularly efficient as 
compared to other polycations, such as lipopolyamine and polylysine (Boussif et al., 
1995), PEI polyplexes can be toxic to cells. This toxicity can be significantly reduced by 
conjugating PEI with polyethylene glycol (PEG). PEGylation of PEI shields the surface 
charges of PEI and prevents the polycation from interacting with other negatively 
charged macromolecules inside the cell; this in turn reduces cytotoxicity (Petersen et al., 
2002). In addition, PEGylation improves transfection efficiency by weakening 
electrostatic interactions between PEI and its nucleic acid cargo, which in turn allows the 
nucleic acid to be easily released into the cytoplasm (Mao et al., 2006). 
1.6. Endocytosis in Oocytes 
Polycations are taken up into cells via endocytosis. Therefore, the ability of 
oocytes to undergo endocytosis is crucial for polycation-mediated delivery to be a 
feasible alternative to microinjection. Oocytes do in fact undergo endocytosis. Lowther et 
al. showed that dynamin and clathrin, two of the most common proteins responsible for 
receptor endocytosis in somatic cells, are expressed in oocytes (2011). They also 
demonstrated that when oocytes were incubated in FM-143, a dye that incorporates into 
the plasma membrane of cells and retains its fluorescence when the membrane is 
endocytosed, fluorescence could be detected in endosomes in the cytoplasm of the 
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oocytes (Lowther, Nikolaev, & Mehlmann, 2011). It has also been shown that receptor-
mediated endocytosis is crucial for some oocyte biological processes, particularly the 
proper regulation of cAMP levels that is required for the maintenance of meiotic arrest 
(Lowther et al., 2011).  cAMP is produced in oocytes by the activity of a constitutively 
active G-protein-coupled receptor 3 (GPR3) and it has been shown that this GPR3 
localizes in the plasma membrane and within early endosomes in the oocyte, which 
indicates that GPR3 is endocytosed (Lowther et al., 2011).  Furthermore, inhibition of 
endocytosis disrupts the proper regulation of cAMP levels (Lowther et al., 2011).   
2.  Thesis Aims and Objectives 
This thesis investigates whether the delivery of nucleic acids into mammalian 
oocytes using polycations may be a potential alternative to microinjection. Lipid-based 
delivery vehicles have been shown in a single study to deliver dsRNA into ZP-free 
oocytes, but it is unclear how effective these vehicles are in transfecting ZP-intact 
oocytes. Moreover, studies examining polycation-mediated delivery in a variety of other 
cell types have shown that polycation-based delivery systems are potentially superior to 
lipid-based systems in many respects. Thus, I sought to examine the potential of 
polycations to deliver nucleic acids into ZP-intact oocytes. In particular, I aimed to test 
the delivery potential of three different types of polycations: PEI, PEGylated PEI, and a 
commercial polycation-based nanoparticle, HappyFect. Unmodified PEI was purchased 
from a manufacturer; PEGylated PEI was made by covalently conjugating PEG to PEI. I 
then used dynamic light scattering and gel mobility shift assays to physically and 
chemically characterize the unmodified PEI and PEGylated PEI based on their size and 
their ability to complex with DNA or RNA. 
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Because PEI and PEG-PEI have been shown to effectively deliver nucleic acids 
into mouse NIH 3T3 cells (Boussif et al., 1995; Petersen et al., 2002), I first tested the 
delivery potential of the three polycations in NIH 3T3 cells before testing them in mouse 
oocytes. To test the delivery potential of the polycations in NIH 3T3 cells, I used the 
polycations as vehicles to deliver siRNAs that target a specific gene, and then examined 
knockdown of the gene at the transcript or protein level. To do this I targeted Ensa with 
an siRNA cocktail that had been shown previously by the Evans lab to knock down 
expression of Ensa mRNA and ENSA protein in oocytes using the gold standard delivery 
method of microinjection (Matthews and Evans, 2014).  
To ensure that the Ensa-targeting siRNA was functional in NIH 3T3 cells, I first 
used Lipofectamine 2000, a lipid-based delivery vehicle, to deliver the siRNA. I showed 
that the Ensa siRNA did achieve knockdown in the NIH 3T3 cells at both the transcript 
and protein level using qPCR and western blots to determine the levels of Ensa mRNA 
and protein respectively in cells transfected with Lipofectamine 2000 and Ensa siRNA. I 
then examined the ability of PEI, PEG-PEI, and HappyFect to deliver the Ensa siRNA 
and knock down Ensa mRNA and protein. These experiments were conducted with 
Lipofectamine 2000 as a positive control delivery vehicle. Because HappyFect was the 
only polycation to achieve significant knockdown of Ensa mRNA and protein in NIH 




Materials and Methods 
1. Synthesis and Physico-chemical Characterization of Polycations 
1.1. Synthesis and Physical Characterization of PEG-PEI 
Synthesis 
PEGylated PEI, containing 25 kD branched polyethylene-imine conjugated to a 
maleimide amine derivative of a 3.4 kD polyethylene glycol was synthesized according 
to the schematic shown in Figure 2 using a protocol from Chen et al. (2012). PEI (Sigma-
Aldrich; 125 mg) was dissolved in 50 mL of 0.1 M HEPES buffer (pH 8.4) and stirred 
overnight. N-succinimidyl-S-acetylthiopropionate (SATP, Thermo Scientific; 12 mg) was 
dissolved in 8 mL of anhydrous DMSO, which was prepared by drying DMSO using 3-
angstrom molecular sieves. SATP (4.8 moles or 1.2 mg) dissolved in 800 µL of DMSO 
was slowly added to 4 mL of the PEI solution (0.4 mol or 10 mg).  The mixture was 
stirred at room temperature for 2 hours, and the resulting product was purified using a 15 
mL 10 kD molecular-weight cut-off centrifuge filtration tube (Amicon). All 
centrifugations described in this section occurred at 4000 x g for 40 minutes. After 
centrifuging once, 400 L of 1X PBS was added to the centrifuge tube and centrifuged 
again. This was repeated 3-4 times until 200 L of the concentrate was left. When PEI 
reacts with SATP, an acetylated PEI molecule containing a protected sulfhydryl group is 
formed.  
The resulting product was deacetylated by treatment with hydroxylamine-
hydrochloric acid. A 400 L aliquot of deacetylating solution, containing 0.5 M 
hydroxylamine-HCl and 25 mM in EDTA in 1X PBS (pH 7.2-7.5), was slowly added to 
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the acetylated PEI from the first step of the synthesis and stirred at room temperature for 
2 hours. The solution was transferred to a 15 mL MW cut-off centrifuge tube and 
centrifuged. After one spin, 400 L of 0.1 M HEPES buffer was added to the centrifuge 
tube and centrifugation was repeated. This process was repeated 3-4 times until 200 L 
of the concentrate was left.  The resulting product is a PEI molecule with a free reactive 
thiol group.  
The free thiol group of PEI was reacted with PEG that was derivatized with a 
maleimide. Maleimide PEG amine  (NANOCS, 13.6 mg or 4moles) dissolved in 1.6 mL 
of anhydrous DMSO was slowly added to the PEI molecule from Step 2.  The reaction 
mixture was transferred to a MW cut-off centrifuge tube. After one spin, 1 mL of water 
was added and centrifugation was repeated. This process was repeated 3-4 times. The 
resulting product was analyzed using dynamic light scattering, lyophilized on a Speed 
Vac, and dissolved in water. The concentration of the PEG-PEI solution was determined 
by weighing the lyophilized product before dissolving in water. The molar ratio of PEI to 
PEG was 1:10. The expected molecular weight is 59 kD assuming that all the PEG reacts 
with the PEI.  
Characterization of PEG-PEI by Dynamic Light Scattering 
Dynamic light scattering was used to characterize the size of PEG-PEI by 
comparing the average hydrodynamic radius of particles in a solution of PEI alone to that 
of a solution of PEG-PEI. PEI or PEG-PEI was dissolved in a HEPES Buffered Saline 
(HBS) solution that contained 20 mM HEPES and 150 mM NaCl. The concentration of 
the PEI solution was 1mg/mL. The concentration of the PEG-PEI solution was unknown 
as the hydrodynamic diameter was measured before lyophilizing the final product. Five 
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aliquots (50 L) of each solution were measured on a DynaPro instrument with 
DYNAMICS software using regularization analysis. Each measurement consisted of 20 
acquisitions, 10 seconds each. The average hydrodynamic radius of 5 measurements as 
well as the standard errors of the measurements were determined, in order to examine 
variation between aliquots of each solution. 
2. Chemical Characterization of Polycations: Polyplex Formation 
2.1 Calculating N/P Ratios 
All experiments involving the formation of polyplexes require calculations of the 
N/P ratio, the ratio of the moles of nitrogen in PEI or PEG-PEI to the moles of phosphate 
in the nucleic acid. As in convention in the field, the N/P ratio will be expressed as one 
number and an N/P ratio of 10, for example, will signify ten moles of nitrogen for every 
one mole of phosphate (Boussif et al., 1995; Petersen et al., 2002; Zhao et al., 2009). In 
each experiment, the amount of nucleic acid was kept constant but the amount of PEI or 
PEG-PEI varied to give different N/P ratios. The moles of phosphate were calculated 
using either the weight of the nucleic acid or the number of base pairs. In the experiments 
using plasmid DNA, 20 ng of plasmid were used to form each complex. The average 
molecular weight of a nucleotide is 330g/mol. Thus, 20 ng of plasmid is equivalent to 61 
pmoles of phosphate (20 x 10-9 g / 330 g/mol). In the experiments using the RNA duplex 
that mimics the Ensa siRNA or the Ensa-targeting siRNA, the number of base pairs was 
used to calculate the moles of phosphate. Both the duplex and the siRNA contained 19-bp 
or 36 phosphates per mole of the duplex. Thus, 10 pmoles of the duplex is equivalent to 
360 pmoles of phosphate (10 x 10-12 moles * 36 phosphates/mol).  
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The moles of nitrogen required to form the complex were calculated based on the 
moles of phosphate multiplied by the N/P ratio. For example, if the desired N/P ratio is 
10 and the complex contains 360 pmoles of phosphate, we would need 3.6 nmoles of 
nitrogen  
Branched 25 kD polyethyleneimine is made up of n repeating units of a monomer, 
C22H55N11, whose molecular weight is 473 D. There are a total of 53 (25,000/473) 
monomer units each containing 11 nitrogens and thus a total of 583 (53 x 11) moles of 
nitrogen in each mole of PEI or PEG-PEI. Therefore at an N/P ratio of 10, 617 pmoles 
(3.6 x 10-9 nitrogens/583 moles of nitrogen/mol) of PEI or PEG-PEI are required to form 
the complex. 
2.2. Complex Formation with a Plasmid 
  pGEM-3Z (165 ng) was treated with 2 L of restriction enzyme EcoRI in a 
solution of 5 µL of EcoRI buffer and 37 L of water. The reaction was incubated for 2 
hours at 37 C. Five aliquots (for 5 complexes) of 20 ng of the linearized plasmid was 
evaporated under vacuum and residue was dissolved in 5 L of HEPES Buffered Saline 
(HBS) solution. PEI or PEG-PEI, dissolved in 5 L of HBS, was added to the 20 ng 
aliquots of the pGEM-3Z at N/P ratios of 1, 5, 10, 15 and 20 (See Table 1 for molar 
amounts of polymers); total volume of each solution was 10 µL. The solutions were 
incubated at room temperature for 20 minutes and loaded onto a 0.8% TAE agarose gel 
(8.3 cm x 5 cm) containing SYBR Green. The gel was run in TAE buffer at 100V for 1 
hour, and the complexes were visualized in the gel using a phosphorimager. 
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2.2 Complex Formation with an RNA Duplex 
The duplex, which mimicked the Ensa-targeting siRNA, contained a FITC labeled 
oligo-2’-O-methylribonucleotide annealed to a complementary RNA. Five pmoles of the 
duplex were used for each complex with PEI or PEG-PEI; a stock solution of duplex was 
made by combining equivalent amounts (300 pmoles) of the FITC-oligo and its 
complementary RNA in 300 µL of HBS; the duplex was heated at 95 C for 5 minutes 
and allowed to slow cool to room temperature for annealing of the strands to occur. To 
confirm duplex formation, 5 µL of the FITC-oligo and the duplex were loaded onto a 
20% native polyacrylamide gel (8 cm x 8 cm) and run in TBE buffer at 100 V. 
Fluorescence was visualized with a phosphorimager. 
PEI or PEG-PEI, dissolved in 5 µL of HBS, was added to 5 µL (5 pmoles) of the 
duplex in HBS at N/P ratios of 5 to 40 at increments of 5 (See Table 2 for molar amounts 
of polycations). The solutions were incubated at room temperature for 20 minutes and 
loaded onto a 1% TBE agarose gel (8.3 cm x 5 cm) and the gel was run in TBE buffer at 
100V for 30 minutes. A phosphorimager was used to visualize the fluorescence of the 
FITC labeled duplex. 
 
3. siRNA Mediated Knockdown of Ensa in NIH 3T3 cells  
3.1 Cell Culture  
For each transfection experiment, mouse NIH 3T3 fibroblast cells were seeded in 
6-well plates at a density of 1 x 105 cells/mL in 2-2.5 mL of Dulbecco’s modified Eagle’s 
medium (DMEM, Gibco by Life Technologies) supplemented with 10% fetal bovine 
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serum (FBS, Gibco by Life Technologies), hereafter referred to as serum-complete 
DMEM, and incubated at 37 C in a 5% CO2 atmosphere overnight. Cells were at 50-
80% confluence for transfection experiments. Transcript level transfection experiments 
were performed in triplicates (three wells of siRNA-treated cells and three wells of 
control cells); protein level transcription experiments were conducted with 1 well of 
siRNA-treated cells and 1 well of control cells. 
3.2. Preparing the Ensa-targeting siRNA  
ON-TARGETplus SMARTpool siRNA (Thermo Scientific) targeting mouse Ensa 
(see Table 3 for sequences; used previously for RNAi-mediated knockdown of Ensa in 
mouse oocytes (Matthews and Evans, 2014)) was dissolved according to manufacturer’s 
instructions, to a concentration of 100 µM in four volumes of RNase-free water and one 
volume of 5X siRNA Buffer. For the transfections, the100 µM siRNA stocks were 
diluted to a 20 µM solution in 1X siRNA buffer.  
3.3. Transfections 
Lipofectamine  
For all transfections using Lipofectamine 2000 as a delivery vehicle, 3 µL of 
Lipofectamine 2000 diluted in 100 µL of OptiMEM (Gibco by Life Technologies) were 
added to 100 pmoles of the Ensa siRNA diluted in 100 µL of OptiMEM, for a total 
transfection mixture volume of 200 µL. For control cells, 3 µL of Lipofectamine 2000 
were diluted in 200 µL of OptiMEM without the siRNA. Solutions were mixed by 
pipetting up and down and incubated at room temperature for 20 minutes. Solutions were 
then added dropwise to cells in 1.8 mL of serum free DMEM (total volume of 2 mL). 
After 4 hours of incubation in 37 C/5% CO2, the medium was replaced with serum- 
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complete DMEM and the cells were cultured for 44-48 hours before the isolation of RNA 
or western blot analysis. 
PEI, and PEG-PEI  
N/P Ratio of 10 
Transfection conditions were adapted from Chen et al. (2012). PEI or PEG-PEI 
(62 pmol) diluted in 100 µL of 1X PBS were added to 100 pmoles of the Ensa siRNA 
diluted in 100 µL of 1X PBS, for a total transfection mixture volume of 200 µL. For 
control cells, 62 pmoles of PEI or PEG-PEI were diluted in 200 µL of 1X PBS without 
the siRNA. Solutions were mixed by pipetting up and down and incubated at room 
temperature for 20 minutes. Solutions were then added dropwise to cells in 1.8 mL of 
serum-complete DMEM (total volume of 2 mL). After 4 hours of incubation in 37 C/5% 
CO2, the medium was replaced with fresh serum-complete DMEM and the cells were 
cultured for 44-48 hours before the isolation of RNA. 
 
N/P Ratio of 20 
Transfection protocol was modified to keep the conditions of complex formation 
the same as those used for the gel mobility shift assays with the RNA duplex. PEI or 
PEG-PEI (124 pmol) diluted in 100 µL of HBS were added to 100 pmoles of the Ensa 
siRNA diluted in 100 µL of HBS, for a total transfection mixture volume of 200 µL. For 
control cells, 124 pmoles of PEI or PEG-PEI were diluted in 200 µL of HBS without the 
siRNA. Solutions were mixed by pipetting up and down, and incubated at room 
temperature for 20 minutes. Solutions were then added dropwise to cells in 1.8 mL of 
serum-free DMEM (total volume of 2 mL). After 4 hours of incubation in 37 C/5% CO2, 
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the medium was replaced with fresh serum-complete DMEM and the cells were cultured 
for 44-48 hours before the isolation of RNA. 
 
HappyFect  
HappyFect was incubated in 37 C for 10 minutes prior to use, vortexed and 
centrifuged quickly. According to manufacturer’s instructions, the suggested amounts of 
HappyFect (Table 4) can be varied +/- 50%. Two separate experiments were performed 
in which two different amounts were tested: 10 µL in a total volume of 2.5 mL of DMEM 
(0.4% HappyFect) or 20 µL in a total volume of 2.5 mL of DMEM (0.8% HappyFect). In 
each experiment, 10 or 20 µL of HappyFect, diluted in 62.5 µL of OptiMEM were added 
to 100 pmoles of the Ensa siRNA, diluted in 62.5 µL of OptiMEM, for a total 
transfection mixture volume of 125 µL. For the control cells, 10 or 20 µL of HappyFect 
were dissolved in 125 µL of OptiMEM without the siRNA. Solutions were incubated at 
room temperature for 20 minutes and 375 µL of serum-free media was added to the 
solutions. The media containing the transfection solutions was then added to the cells 
along with an additional 2 mL of fresh serum-free media (for a total volume of 2.5 mL). 
After 4 hours of incubation in 37 C/5% CO2, media was replaced with serum-complete 








3.4. Evaluating Knockdown at the Transcript Level 
RNA Extraction/cDNA Synthesis   
RNA was isolated from NIH 3T3 cells using the 5 PRIME PerfectPure RNA 
Cultured Cell Kit. PerfectPure Lysis Solution (400 µL) was added directly to each well of 
cells. Cells were scraped and the cell lysate was pippetted up and down for thorough 
homogenization. Cell lysate was then added to a purification column where RNA was 
bound to a membrane and washed with buffers provided in the kit. During the 
purification, the column was treated with DNase for 15 minutes according to 
manufacturer’s instructions. RNA was eluted in an elution buffer containing DEPC-
treated water and RNA was converted to cDNA using the iScript cDNA Synthesis Kit 
(Bio-Rad). The total volume of each cDNA reaction was 20 µL, which contained 0.5 -1 
µg of RNA, 4 uL of the 5X iScript buffer, 1µL of iScript reverse transcriptase, and 
nuclease free water.  
RT-qPCR 
  Quantitative PCR was performed using primers specific to mouse Ensa and a 
reference gene, glyceraldehyde 3-phosphate dehydrogenase (Gapdh) (See Table 5 for 
primer sequences). To calculate primer efficiencies, standard curves were made by 
preparing reactions with serial dilutions of the template, NIH 3T3 cDNA. All qPCR 
reactions were prepared using 10 µL of SsoAdvanced SYBR Green Supermix (Bio-Rad), 
1.5 µL of a 5 µM primer solution containing forward and reverse Ensa or Gapdh primers, 
3.5 µL of nuclease-free water, and 5 µL of template, for a total volume of 20 µL. Ensa 
and Gapdh mRNA levels were detected with a CFX96 Real-Time PCR Detection 
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Instrument using the following cycle conditions: 95C for 2 minutes, followed by 35 
cycles of 95C for 15 seconds, 55C for 20 seconds and 72C for 30 seconds.  Cycle 
Threshold (Ct) values of all samples were recorded, and fold changes (Ct ) were 
calculated by normalizing Ensa expression against Gapdh expression.  
3.5 Evaluating Knockdown at the Protein Level 
Prior to western blot analysis, cells were suspended in 300 uL of SDS-PAGE 
sample buffer (3% SDS, 10% glycerol, 0.02% bromophenol blue, 4% 2-mercaptoethanol, 
65 mM TRIS-HCl, pH 6.8) and cell lysate was sonicated. Samples were then boiled at 
100 C for 10 minutes and various amounts of the control cell lysate and the Ensa siRNA 
lysate were loaded onto a 12.5% polyacrylamide SDS-gel to separate the proteins.  
 Western Blot for Lipofectamine Transfections 
Lipofectamine knockdown experiments were performed in collaboration with 
Lauren Matthews; I performed cell culture work, transfection, RNA extraction, cDNA 
synthesis, and RT-qPCR (described above); LM performed protein extraction and 
immunoblotting. Two separate gels were run for each antibody (ENSA and Actin) with 
different amounts of cell lysate because the Actin signal was saturated when the 
minimum amount of cell lysate required for the ENSA signal was loaded onto the gel. 
Thus, to stay within linear range of detection, for the anti-ENSA blot, 0.5, 1, 2, and 5 µL 
of cell lysate was loaded onto the gel and for the anti-Actin blot, 0.025, 0.05, 0.1, and 
0.25 µL of cell lysate was loaded onto the gel. The proteins were transferred to two 
Immobilon-P PVDF membranes (Millipore) and each membrane was probed with Actin 
(50kD) and ENSA (25 kD) separately.  
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Actin 
The membrane was blocked overnight in 5% dry milk in PBS-T (PBS containing 
0.1% Tween-20 (Sigma-Aldrich). The membrane was then incubated with 10 mL of an 
anti-ACTIN antibody (Santa Cruz Biotechnology; made against full-length mouse Actin; 
diluted 1:20,000 in PBS-T + 5% BSA + 0.02% NaN3) for 1 hour, washed 3 times with 
PBS-T, and then incubated with a goat anti-mouse IgG-horseradish peroxidase (HRP) 
(Thermo Scientific; diluted 1:20,000 in PBS-T + 3% BSA) for 1 hour, followed by 3 
washes with PBS-T.  
ENSA 
The membrane was blocked overnight in 10% cold-water fish gelatin in PBS-T.  
The membrane was then incubated with an anti-ENSA antibody (Santa Cruz 
Biotechnology; made against full-length human ENSA; diluted 1:400 in PBS-T 
containing 3% BSA and 0.012% NaN3) for 2 hours, washed 3 times with PBS-T, and then 
incubated with a goat anti-rabbit IgG-horseradish peroxidase (HRP) (Jackson 
Immunoresearch; diluted 1:2000 in PBS-T plus 3% BSA) for 1.5 hours, followed by 3 
washes with PBS-T.  
Protein Detection 
The membranes were incubated in Supersignal West Pico Chemiluminescent 
substrate (Thermo Scientific) for 5 minutes and exposed to X-ray film. X-ray film was 
scanned using an HP LaserJet 3390 scanner and ImageJ software was used to analyze 
band intensity. ImageJ software was used to analyze band intensity. The rectangular 
selection tool was used to select each band, and peak intensity was determined. The area 
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under each peak was calculated as a measure of band intensity. To calculate knockdown, 
the ENSA bands of 0.5 µL of cell lysate were normalized to the Actin bands of 0.1 µL of 
cell lysate. 
 Western Blot for HappyFect Transfections 
One gel was loaded with 1, 5, 10, and 15 µL of cell lysate. Proteins were 
transferred to a 0.45 µm nitrocellulose membrane (BioRad). After the transfer, the 
membrane was cut at the 31 kD line of the ladder to probe for GAPDH (37 kD) and 
ENSA (25 kD) separately.  The ENSA blotting protocol is the same as that used for the 
western blots for the Lipofectamine transfections.  
GAPDH 
The membrane was blocked overnight in 5% dry milk in PBS-T (PBS containing 
0.1% Tween-20 (Sigma-Aldrich). The membrane was then incubated with an anti-
GAPDH antibody (Santa Cruz Biotechnology; made against full-length mouse GAPDH; 
diluted 1:5000 in blocking solution) for 1 hour, washed 3 times with PBS-T, and then 
incubated with a goat anti-mouse IgG-horseradish peroxidase (HRP) (Thermo Scientific; 
diluted 1:5000 in the blocking solution) for 1 hour, followed by 3 washes with PBS-T.  
Protein Detection 
Membranes were incubated in Supersignal West Pico Chemiluminescent substrate 
(Thermo Scientific) for approximately 5 minutes and scanned using a FluorChem Q 
imaging system. ImageJ software was used to analyze band intensity, as described for the 
Lipofectamine blot. To calculate knockdown, the intensities of the ENSA bands were 
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normalized to the intensities of the GAPDH bands obtained with the same amount cell 
lysate and the knockdown percentages were averaged.  
4. Uptake of the FITC-Duplex using PEI as a delivery Vehicle  
4.1 Cell Culture 
Mouse NIH 3T3 fibroblast cells were seeded in glass bottom culture dishes at a 
density of 2 x 105 cells/mL in 2 mL of DMEM with FBS and incubated at 37 C and a 
5% CO2 atmosphere overnight.  Cells were at 50-80% confluence before transfection 
experiments were performed. 
4.2. Transfection 
PEI or PEG-PEI (741 pmol), diluted in 250 µL of HBS, was added to 600 pmoles 
of the FITC-duplex diluted in 250 µL of HBS, for a total transfection mixture volume of 
500 µL (N/P ratio of 20).  Lipofectamine was used as a positive control. Lipofectamine 
2000 (12 µL) was diluted in 250 µL of OptiMEM and added to 600 pmoles of the FITC-
duplex diluted in 250 µL of OptiMEM, for a total transfection mixture volume of 500 µL. 
Solutions were mixed by pipetting up and down and incubated at room temperature for 
20 minutes. Solutions were then added dropwise to cells in 1.5 mL of serum-free DMEM 
(total volume of 2 mL). After 4 hours of incubation in 37 C/5% CO2, the medium was 
replaced with serum complete DMEM. Following a culture period of 24 hours, cells were 
examined under a microscope. 
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4.3. Live Cell Microscopy 
Microscopic imaging was performed on a Zeiss Axio Observer Z1 microscope 
and AxioVision software. Images were taken with 10X resolution using differential 
interference contrast (DIC). 
5. Treatment of oocytes with HappyFect to introduce Ensa-targeting siRNA 
5.1 Oocyte Collection and Culture 
Animals were used in accordance with the guidelines of the Johns Hopkins 
University Animal Care and Use committee. Germinal vesicle-intact (GVI) (prophase I-
arrested) oocytes were collected from 6-8-week-old female CF-1 mice (Harlan, 
Indianapolis, IN) in Whitten's-HEPES medium (109.5 mM NaCl, 4.7 mM KCl, 1.2 mM 
KH2PO4, 1.2 mM MgSO4, 5.5 mM glucose, 0.23 mM pyruvic acid, 4.8 mM lactic acid 
hemicalcium salt (Whitten, 1971), supplemented with 7 mM NaHCO3 and 15 mM 
HEPES). Dibutyryl cAMP (dbCAMP, 0.25 mM) was added to culture medium to 
maintain prophase I arrest (Cho, Stern, & Biggers, 1974). Ovaries were punctured with 
syringe needles to release oocyte-cumulus complexes from ovarian follicles, and cumulus 
cells were removed from the oocytes by pipetting oocyte-cumulus complexes through a 
thin-bore pipette. Oocytes were then transferred to Whitten’s-Bicarbonate medium 
containing 0.05% PVA and 0.25 mM dbcAMP for culture (hereafter referred to as WB 
medium), and allowed to recover for 1 hour in 37 C and a 5% CO2 atmosphere.  
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5.2 Transfection using HappyFect 
Oocytes were treated with HappyFect, following the manufacturer’s suggested 
protocol for 10 pmoles of siRNA (Table 4). Since the amounts of HappyFect could be 
varied +/- 50%, as a preliminary experiment, 25 oocytes were transferred to a 35 µL drop 
of a solution containing 1µL of HappyFect in 500 µL of WB medium (0.2% HappyFect) 
and 25 oocytes were transferred to a 35 µL drop of a solution containing 2µL of 
HappyFect in 500 µL of WB medium (0.4% HappyFect). 
As in the experiments with NIH 3T3 cells, prior to the transfection, HappyFect 
was incubated in 37 C for 10 minutes, vortexed and centrifuged quickly. During the 
transfection, 1 µL of HappyFect was added to 10 pmoles of the Ensa siRNA in 25 µL of 
OptiMEM. For the control cells, 1 µL of HappyFect was added to 10 pmoles of a 
negative control siRNA (On-TARGETplus control pool (Dharmacon)) in 25 µL of 
OptiMEM. Solutions were incubated at room temperature for 20 minutes and then diluted 
in 500 µL of WB medium. Sixty oocytes were transferred to a 35 µL drop of the solution 
containing HappyFect and the Ensa siRNA and 60 oocytes were transferred to a 35 µL 
drop of the solution containing HappyFect and the negative control siRNA. Additionally, 
as a visual control for toxicity, 20 oocytes were transferred to a drop containing only WB 
medium. After 4 hours of incubation in 37 C/5% CO2, oocytes treated with HappyFect 
were washed by transferring to 5 different drops of WB media. Finally, all oocytes were 
transferred to a fresh drop of WB medium and cultured in 37 C/5 % CO2 for 44-48 
hours.   
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5.3. Evaluating Knockdown at the Protein Level 
Western Blots 
Prior to western blot analysis, 20 oocytes from each experimental group were 
suspended in 10 µL of SDS-PAGE sample buffer (3% SDS, 10% glycerol, 0.02% 
bromophenol blue, 4% 2-mercaptoethanol, 65 mM TRIS-HCl, pH 6.8). Samples were 
boiled at 100 C for 10 minutes and loaded onto a 12.5% polyacrylamide SDS-gel to 
separate the proteins. Proteins were transferred to an Immobilon-P PVDF membrane. 
After the transfer, the membrane was cut at the 31 kD line of the ladder to probe for 
GAPDH (37 kD) and ENSA (25 kD) separately. The blotting protocol using the anti-
ENSA was the same as that used for the NIH-3T3 cell lysates. For the anti-GAPDH blot, 
the membrane was blocked overnight in 5% dry milk in PBS-T, incubated with an anti-
GAPDH antibody diluted 1:3000 in PBS-T + 3% BSA) for 1 hour, washed 3 times with 
PBS-T, and then incubated with a goat anti-mouse IgG-horseradish peroxidase (HRP) 
diluted 1:3000 in PBS-T + 3% BSA) for 1 hour, followed by 3 washes with PBS-T.  
Protein Detection 
The membrane was incubated in Supersignal West Pico Chemiluminescent 
substrate (Thermo Scientific) for 5 minutes and exposed to X-ray film. X-ray film was 
scanned using an HP LaserJet 3390 scanner and ImageJ software was used to analyze 





1. Synthesis and Physico-chemical Characterization of Polycations 
1.1. Synthesis and Physical Characterization of PEG-PEI 
After synthesizing PEGylated PEI, containing 25 kD branched polyethylene-
imine conjugated to a maleimide amine derivative of a 3.4 kD polyethylene glycol, the 
size of unmodified PEI and PEGylated PEI was characterized using dynamic light 
scattering, based on the fact that PEGylated PEI is expected to have a larger molecular 
weight than PEI alone. As determined by five different measurements of PEI or PEG-PEI 
solutions, the average hydrodynamic radius of PEI was smaller than that of PEG-PEI, 
consistent with the formation of PEG conjugates on PEI (Figure 3). 
2. Chemical Characterization of Polycations: Polyplex Formation 
2.1. Complex Formation with a Plasmid  
To assess the ability of PEI, and PEG-PEI to complex with nucleic acids, I first 
determined whether the polycations could complex with plasmid DNA, using gel 
mobility shift assays adapted from Zhang et al. (2004). Linearized pGEM-3Z plasmid and 
PEI or PEGylated PEI were combined at different N/P ratios, and loaded onto an agarose 
gel. The agarose gels contained SYBR green, a dye that binds to DNA; complete 
complexation occurs when SYBR green is excluded from the complex and is unable to 
bind to the plasmid, resulting in the disappearance of the dye on the gel. When 
PEGylated PEI or PEI was added to the linearized pGEM plasmid and loaded onto a gel, 
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PEI formed a complex with the plasmid at N/P ratios 10, while PEG-PEI formed a 
complex with the plasmid at N/P ratios  5 (Figure 4). 
2.2 Complex Formation with a Duplex 
Because I used siRNA mediated knockdown as a functional assay to examine 
whether PEI or PEG-PEI would deliver nucleic acids into cells, it was important to 
investigate whether the polymers could complex with siRNA in addition to plasmids. 
Moreover, due to the possibility that the polymers do not form complexes with siRNA at 
the same N/P ratios that they form complexes with plasmid DNA, gel mobility shift 
experiments adapted from Li et al. (2010) were conducted with a duplex that mimics the 
Ensa siRNA. The duplex contained a FITC labeled oligo-2’-O-methylribonucleotide (19 
nucleotides in length) annealed to a complementary RNA. First, to assess duplex 
formation, the FITC-oligo and the duplex were loaded onto a native polyacrylamide gel 
(Figure 5A). The shift in mobility of the duplex as compared with the FITC-oligo 
confirmed duplex formation.  
PEGylated PEI or PEI was added to the FITC labeled duplex at varying N/P 
ratios, and complexes were loaded onto an agarose gel as shown in Figure 5B. Quenching 
of the FITC fluorescence indicates polyplex formation (Li et al., 2010). Although PEI 
formed a complex with the duplex at N/P ratios  20, it is unclear if the decrease in 
fluorescence intensity seen with PEG-PEI is due to complex formation. 
 30 
3. siRNA Mediated Knockdown of Ensa in NIH 3T3 cells  
Recent work in the Evans lab demonstrated that the protein α-endosulfine (ENSA) 
plays a role in the exit of oocytes from prophase I arrest (Matthews and Evans, 2014).   
These studies utilized oocytes microinjected with negative control siRNA or with Ensa-
targeting siRNA; the injected oocytes were then cultured in conditions to maintain 
prophase I arrest to allow time for knockdown of the target Ensa mRNA to occur 
(Matthews & Evans, 2014). Following a 44-48 hour culture period, Ensa mRNA levels 
decreased by 67 ± 11% and ENSA protein levels decreased by 80 ± 6% in Ensa siRNA-
injected oocytes as compared with controls (Matthews & Evans, 2014).  Before 
examining the ability of the polycations to deliver the Ensa siRNA, I needed to make sure 
the siRNA cocktail functions in NIH 3T3 cells. To assess the ability of the Ensa siRNA 
to effectively knock down Ensa expression in NIH 3T3 cells, I first used Lipofectamine 
2000 as a delivery vehicle because it is known to deliver DNA or RNA into this cell type 
(Elbashir et al., 2001). 
 
Use of Lipofectamine to Introduce the Ensa-targeting siRNA 
Triplicates of NIH 3T3 cells were transfected with Lipofectamine 2000 (control) 
or a complex consisting of Lipofectamine 2000 and the Ensa siRNA.  Following a culture 
period of 44-48 hours, RNA was extracted from the cells and reverse-transcribed to 
cDNA. Two different amounts of siRNA (50 pmol and 100 pmol) and three different 
volumes of Lipofectamine 2000 were tested.  
RT-qPCR of cDNA from transfected cells was used to evaluate knockdown of 
Ensa mRNA, using primers specific to Ensa and a reference gene, Gapdh. Preliminary 
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experiments were conducted to investigate the efficiency of the primers.  The efficiency 
of each primer set was between 90-110% and the R2 values were > 0.99 (Figure 6). 
Although 50 pmoles of siRNA did not achieve significant knockdown at the ratios tested 
(data not shown), 100 pmoles of siRNA achieved ~50% knockdown of Ensa mRNA 
levels as compared with control cells when combined with 3 µL of Lipofectamine 2000 
(Figure 7A). 
Similar transfection experiments were conducted to examine knockdown at the 
protein level. Following a culture period of 44-48 hours, ENSA protein levels decreased 
by ~ 49% in cells treated with the Ensa-targeting siRNA as compared with control cells, 
which is consistent with the knockdown at the transcript level (Figure 7B; immunoblot 
performed by Lauren Matthews). Since Lipofectamine 2000 effectively delivered the 
Ensa siRNA, it served as a positive control in all transfection experiments. 
 
Use of PEI or PEGylated PEI to introduce Ensa-targeting siRNA 
Based on the gel mobility shift experiments with plasmid DNA (Figure 4), it 
appeared that PEI and PEG-PEI were capable of forming complexes with the plasmid at 
N/P ratios 10 and  5 respectively. To investigate the ability of PEI and PEG-PEI to 
deliver the Ensa siRNA, triplicates of NIH 3T3 cells were transfected with a complex 
consisting of PEI or PEG-PEI and the Ensa siRNA at an N/P ratio of 10, or with PEI or 
PEG-PEI alone (control cells). For comparison to a positive control, triplicates of cells 
were also transfected with a complex of Lipofectamine 2000 and the Ensa siRNA or with 
Lipofectamine 2000 alone (control cells).  Following a culture period of 44-48 hours 
there was no significant change in Ensa mRNA levels in cells treated with the complex of 
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Ensa siRNA and PEI or PEG-PEI compared with control cells (Figure 8A). However, 
Ensa mRNA levels in cells treated with the complex of Ensa siRNA and Lipofectamine 
decreased by ~ 25% compared with control cells.  
One explanation for the inability of PEI or PEG-PEI to achieve knockdown at an 
N/P ratio of 10, could be that the polymers failed to form complexes with the Ensa 
siRNA. To investigate complex formation further, we conducted the gel mobility shift 
assays with an RNA duplex that mimics the Ensa siRNA. While gel shift mobility assays 
indicated that both PEI and PEG-PEI could complex with plasmid DNA, the experiments 
performed with the RNA duplex suggested that PEG-PEI failed to form a complex with 
the duplex. With these results raising questions about the ability of PEG-PEI to form 
complexes with Ensa siRNA, we did not pursue further transfection experiments with the 
PEG-PEI, and instead focused on the delivery potential of unmodified PEI.  
Because the gel mobility shift assays with the RNA duplex showed that PEI forms 
a complex with the duplex at N/P ratios  20, we wanted to assess whether PEI could 
deliver the Ensa siRNA into NIH 3T3 cells at an N/P ratio of 20. Thus, transfection 
experiments were conducted using an N/P ratio of 20 instead of 10. Following a culture 
period of 44-48 hours, Ensa mRNA levels in cells treated with Ensa siRNA and PEI only 
decreased by ~15% compared with control cells (Figure 8B), but the difference in Ensa 
mRNA levels was not statistically significant between cells treated with PEI + Ensa-
targeting siRNA and cells treated with PEI only. On the other hand, in the same 
experiment, Ensa mRNA levels in cells treated with Ensa siRNA and Lipofectamine 
2000 decreased by ~ 50%.  
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Use of HappyFect to Introduce the Ensa-targeting siRNA 
Since PEI did not achieve significant knockdown under the conditions tested in 
these experiments, we investigated the ability of a commercially available polycation-
based nanoparticle, HappyFect, to deliver the Ensa siRNA and knock down Ensa 
expression in NIH 3T3 cells. HappyFect was developed by scientists at Tecrea Ltd to 
overcome major limitations of existing transfection procedures, particularly poor 
efficiency and unacceptable levels of toxicity (information provided by the manufacturer, 
Tecrea Ltd). Combining HappyFect with RNA or DNA results in the rapid assembly of 
nanoparticles and the subsequent entry of the RNA or DNA into the cytoplasm of 
mammalian cells. HappyFect has been used in a wide variety of cell types (Tecrea Ltd). It 
can be used with even the most sensitive primary cells and the chemistry is compatible 
with in vivo applications (Tecrea Ltd).  
Triplicates of NIH 3T3 cells were transfected with a complex consisting of 
HappyFect and the Ensa siRNA or with HappyFect alone.  Two different amounts of 
HappyFect were tested. As a positive control, cells were also transfected with a complex 
consisting of Lipofectamine 2000 and the Ensa siRNA or with Lipofectamine 2000 
alone. Following a culture period of 44-48 hours, Ensa mRNA levels in cells treated with 
Ensa siRNA and 10 µL of HappyFect in 2.5 mL of DMEM (0.4% HappyFect) decreased 
by ~9% compared with control cells; Ensa mRNA levels in cells treated with the Ensa 
siRNA and Lipofectamine 2000 decreased by ~26%, but neither result was statistically 
significant as error bars/confidence intervals overlap (Figure 9A). Ensa mRNA levels in 
cells treated with Ensa siRNA and 20 µL of HappyFect in 2.5 mL of DMEM (0.8% 
HappyFect) significantly decreased by ~36% compared with control cells, while Ensa 
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mRNA levels in cells treated with Ensa siRNA and Lipofectamine 2000 decreased by 
about 25%; knockdown with Lipofectamine 2000 in this experiment was not statistically 
significant (Figure 9B).   
Similar transfection experiments were conducted to examine knockdown at the 
protein level, using 10 µL of HappyFect. Following a culture period of 44-48 hours, 
ENSA protein levels decreased by ~11% in treated cells compared with control cells 
(Figure 9C). I did not assess protein level knockdown using 20 µL of HappyFect because 
the cells had shown signs of toxicity when the transfection experiment was repeated.  
4. Uptake of the FITC-Duplex using PEI as a Delivery Vehicle  
 The gel mobility shift assays indicated that PEI formed complexes with both 
plasmid DNA and a duplex that mimics the Ensa siRNA. However, when PEI was used 
to deliver the Ensa siRNA, at the N/P ratio (20) at which it formed a complex with the 
FITC-duplex, no significant knockdown was achieved. Althought it is possible that the 
PEI can form a complex with the FITC-duplex that mimicked the siRNA but not the 
actual Ensa siRNA, another explanation is that the polyplex was not actually endocytosed 
into the NIH 3T3 cells. To determine if the PEI was able to mediate cellular entry of 
nucleic acids at an N/P ratio of 20, I examined uptake of the polyplex formed with the 
FITC labeled duplex and PEI. As a positive control, uptake of a complex formed between 
Lipofectamine 2000 and the FITC-duplex was also examined. Duplex fluorescence could 
be seen 24 hours following the transfection in both NIH 3T3 cells transfected with PEI 
and Lipofectamine 2000 (Figure 10).  However, some of the cells transfected with PEI 
and the FITC-oligo appear to show signs of cytoxicity.   
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5. Treatment of oocytes with HappyFect to introduce Ensa-targeting siRNA 
 Since HappyFect was the only polycation to achieve some knockdown (~36% at 
the transcript level), I wanted to test the ability of HappyFect to deliver the Ensa siRNA 
into mouse oocytes. Preliminary experiments were performed in which oocytes were 
transferred to a 35 µL drop of a 0.2 or 0.4% HappyFect solution. After a 4 hour treatment 
with the HappyFect, 24% (6/25) of the oocytes treated with the 0.2% HappyFect solution 
had died or appeared unhealthy, while 44% (11/25) of the oocytes treated with the 0.4% 
HappyFect solution had died or appeared unhealthy.  Thus, to introduce the Ensa siRNA 
into oocytes, the 0.2% HappyFect solution was chosen for the transfection protocol.  
 For the transfection, 60 oocytes were treated with a complex of HappyFect and 
the Ensa siRNA, and 60 oocytes were treated with a complex of HappyFect and a 
negative control siRNA.  As an additional control, 20 oocytes were cultured in parallel in 
plain WB-medium; these cells were assessed periodically, to compare the visual 
appearance of these oocytes in the absence of HappyFect to oocytes in the presence of 
HappyFect. Following a culture period of 44-48 hours, 31% of the oocytes (19/60) 
treated with the negative control siRNA and 18% of the Ensa siRNA-treated oocytes 
(11/60) had died or appeared unhealthy; all of the untreated oocytes remained 
healthy/alive. An immunoblot analysis of the protein levels in 20 untreated oocytes, 20 
oocytes treated with HappyFect and Ensa siRNA, and 20 oocytes treated with HappyFect 
and negative control siRNA, showed that no knockdown of ENSA was achieved as the 
intensity of both the ENSA and GAPDH (loading control) bands were approximately 
equivalent in all three groups (Figure 12).  
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Discussion 
1. Requirements of Polycation-mediated Nucleic Acid Delivery 
The delivery of nucleic acids using polycations is a multi-faceted process that is 
dependent on the condensation of DNA, cellular uptake, release of the nucleic acid from 
the polyplex, and many other factors. Recent studies have shown that the efficiency of 
polycation-mediated delivery varies with the N/P ratio; particularly, transfection 
efficiency has been shown to increase with the use of excess polycations (Boeckle et al., 
2004; Dai, Gjetting, Mattebjerg, Wu, & Andresen, 2011). However, since increasing N/P 
ratios incurs toxic effects on cells, cytotoxicity is another important consideration. 
Successful siRNA-mediated knockdown requires the optimization of all the features that 
influence polycation-mediated delivery as well as the essential features intrinsic to RNAi. 
According to my results, although the commercially available polycation-based 
nanoparticle HappyFect was able to knock down Ensa in NIH 3T3 cells at the transcript 
level (Figure 9B), neither PEI nor PEGylated PEI was able to knock down Ensa 
transcripts. However, HappyFect was unable to knock down ENSA protein levels in 
mouse oocytes, under the conditions tested in this thesis (Figure 11). These results may 
be explained by the inability of the polycations to meet any one of the essential 
requirements of effective polycation-mediated delivery.  
 
1.1. Nucleic Acid Condensation 
The condensation of DNA or RNA into small particles by polycations is 
necessary for the efficient delivery of nucleic acids into cells. Because nucleic acid 
condensation is dependent on electrostatic interactions between the polycation and DNA 
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or RNA, complex formation is a function of the N/P ratio.  However, along with the N/P 
ratio, complex formation is also dependent on a number of other factors as well, 
including the charge density of the polymer and the ionic strength of the solvent in which 
polyplexes are formed.  
The binding of nucleic acids to PEI is thought to be mainly driven by entropic 
forces arising from the release of counter ions (Neu et al., 2005). Polycations with a high 
charge density, such as PEI, can release more counter ions upon binding with DNA and 
therefore form more stable complexes (Bronich, Kabanov, & Marky, 2001). Moreover, a 
lower charge density has been shown to impair the condensation capability of polycations 
(Wolfert & Seymour, 1996). PEGylation of PEI provides steric shielding of the PEI 
moiety, to improve complex solubility (Kichler, Chillon, Leborgne, Danos, & Frisch, 
2002) and aggregation (Tang et al., 2003), and to reduce the interaction between PEI and 
proteins or other negatively charged components in cells (Tang et al., 2003). As a result, 
PEGylated PEI tends to be less toxic than unmodified polymers in vitro and in vivo 
(Petersen et al., 2002). However, since a high positive charge density is necessary for the 
condensation of DNA, the addition of PEG can alter the complex-forming behavior of 
PEI and render DNA condensation more difficult, due to the steric layer that shields the 
charged PEI. In particular, studies have shown that while PEG conjugates with molecular 
weights ranging from 350-1900 Da (Sung et al., 2003) did not have a significant effect on 
the complex-forming behavior as a function of the N/P ratio, the complex-forming ability 
of PEIs grafted to a varied number of higher MW PEGs (5 kD) was hindered slightly 
(Petersen et al., 2002). Gel mobility shift assays with the PEGylated PEI used in this 
thesis showed that while PEI formed a complex with an RNA duplex that mimics siRNA, 
 38 
PEGylated PEI failed to form a complex with the duplex (Figure 5). One possible 
explanation for these results is that the steric stabilization of PEI by the PEG conjugates 
reduced the charge density of PEI and therefore hindered polyplex formation. Moreover, 
the duplex that was used to mimic the siRNA contained an oligo-2'-O-
methylribonucleotide annealed to a complementary RNA; the methyl group may have 
contributed to the reduction of the charge density of the polyplex, further impeding 
complex formation. Although this raises the question of whether it is possible that the 
PEG-PEI was able to form a complex with the Ensa siRNA but not the RNA duplex, the 
inability of PEG-PEI to transfect NIH 3T3 cells is convincing evidence that the 
PEGylated PEI does not form a complex with either the RNA duplex or the Ensa siRNA.  
Another important factor of DNA condensation is the medium in which 
complexes are prepared. The size of PEI/DNA complexes formed in saline solutions is 
thought to be dependent on the ionic strength of the solution, and the tendency of 
complex sizes to increase with increasing saline concentration is thought to reflect a 
decreased binding affinity between polycations and nucleic acids (Kabanov & Kabanov, 
1998; Ogris et al., 1998). Because of the reduced binding affinity, higher salt 
concentrations can result in the dissociation of polyplexes; as a result, it is possible that 
PEGylated PEI did not form a complex with either the Ensa siRNA or the RNA duplex 
due to the high ionic strength of the solution in which the complexes were prepared. One 
study reported a drastic decrease of complex size when comparing complexes prepared in 
physiological salt solution with those in 5% glucose (Goula et al., 1998). Future 
experiments could involve changing the conditions of the medium in which the 
complexes of PEGylated PEI and the Ensa siRNA are formed.  
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 Additionally, as reported by Zintchenko et al., since siRNAs are very small 
molecules, the limited electrostatic interaction with polycations to achieve sufficient 
complex stability is a general problem for cationic synthetic carriers (2008). One study 
has shown that the stability of branched PEI polyplexes against salt dissociation is nearly 
two times higher for plasmid DNA as compared to siRNA polyplexes (Zintchenko, 
Philipp, Dehshahri, & Wagner, 2008). Since PEGylated PEI formed a complex with the 
plasmid DNA but not the RNA duplex, it is possible that the polyplexes formed between 
PEG-PEI and the pGEM-3Z plasmid were stable enough to prevent dissociation caused 
by high salt concentrations, but the polyplexes between PEG-PEI and the RNA duplex 
were unstable and dissociated due to the ionic strength of the medium in which they were 
prepared.  
 
1.2 Cellular Uptake 
  The transfection efficiency of polyplexes can vary largely depending on the cell 
type (Gebhart & Kabanov, 2001), possibly due to differences in endocytosis and 
intracellular transport of polyplexes. Fluorescence microscopy experiments investigating 
the delivery of a FITC-labeled duplex into NIH 3T3 cells using PEI as a delivery vehicle 
suggested that the PEI was capable of mediating cellular entry of a duplex (Figure 10). 
Knockdown of Ensa mRNA levels in cells transfected with HappyFect and the Ensa 
siRNA (Figure 9B) indicated that HappyFect was also able to mediate cellular entry of 
siRNA. 
The ability of HappyFect to introduce nucleic acids into oocytes could rely on a 
number of factors.  The positive surface charge of polycation/DNA complexes serves to 
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bind to cells via electrostatic interactions with negatively charged proteoglycans of the 
cell membrane. Recent studies have indicated that these interactions with proteoglycans 
may also be essential for the subsequent process of internalization of the polyplexes 
(Uyechi, Gagne, Thurston, & Szoka, 2001). As a result, a greater density of negatively 
charged proteoglycans on the surface of a particular cell type is believed to enhance 
polycation-mediated delivery (Kircheis, Wightman, & Wagner, 2001a). Some cell types, 
such as melanoma cells, have been shown to achieve better uptake of positively charged 
PEI/DNA complexes because of a large presence of negatively charged cell-surface 
proteoglycans (Kircheis et al., 2001a).  Additionally, to enhance cellular uptake and 
increase transfection efficiency, efforts have been made to combine the non-specific 
electrostatic polyplex-cell surface interaction with the specific mechanism of receptor-
mediated cellular uptake by incorporating cell-binding ligands into transfection 
complexes (Kircheis, Wightman, & Wagner, 2001b). The ability of HappyFect to 
mediate cellular entry of siRNAs into oocytes may depend on the proteoglycans on the 
cell membrane, and incorporating an oocyte cell-binding ligand could improve cellular 
uptake of polyplexes.  
Additionally, the zona pellucida has been shown to act as a barrier in transfections 
of oocytes using lipid-based delivery vehicles (Carballada, Relloso, & Esponda, 2002); it 
is possible that the ZP may be a potential barrier for HappyFect in delivering the Ensa 
siRNA into oocytes and that removal of the ZP may be necessary for polycation-
mediated delivery in oocytes.  
 41 
1.3. Release of Nucleic Acid from the Polyplex 
 For RNAi mediated knockdown to occur, once polyplexes are released from 
endosomes, the siRNA must enter the cytosol and associate with its complementary 
mRNA to either target cleavage of the mRNA or translational arrest. To guarantee 
biological activity of the siRNA, polyplexes should be sufficiently stable during 
endocytosis to ensure intracellular uptake of the siRNA, but the siRNA must also be 
released from the polyplex into the cytosol for subsequent association with its target. 
PEGylation of PEI has been shown to destabilize PEI/siRNA polyplexes, leading to 
increased siRNA release in the cytoplasm and therefore more efficient knockdown 
(Petersen et al., 2002). Although the PEGylated PEI used in this thesis research failed to 
form complexes with the RNA duplex mimicking the Ensa siRNA, the PEI readily 
formed complexes with both the plasmid DNA and the RNA duplex. One possible 
explanation for the inability of PEI to knockdown Ensa mRNA in NIH 3T3 cells could be 
that the complexes of PEI and the Ensa siRNA were too stable, preventing the release of 
the Ensa siRNA from the polyplexes inside the cytosol and its association with Ensa 
mRNA. Other polycations may be feasible alternatives. Novel arginine grafted 
bioreducible polymers, for example, have been engineered to electrostatically interact 
with negatively charged siRNA, form stable complexes, and to release siRNA into the 
cytosol through intracellular cleavage of a bioreducible backbone (Kim, Jeong, Kim, 
Kim, & Bull, 2009). 
 42 
1.4. Balance between cytotoxicity and transfection efficiency 
Generally, the N/P ratio at which polyplexes are formed is not necessarily the 
optimal N/P ratio for transfection. For efficient transfection, PEI polyplexes are usually 
generated with an excess of PEI, where a considerable amount of PEI is free in solution 
(Clamme, Azoulay, & Mely, 2003; Finsinger, Remy, Erbacher, Koch, & Plank, 2000). 
Boeckle et al., purified polyplexes, consisting of PEI and plasmid DNA, through size 
exclusion chromatography to remove free polycations and transfected cells with either 
purified polyplexes or non-purified polyplexes (2004). Not only was the transfection 
efficiency of non-purified particles greater than that of purified particles, but also the 
addition of free PEI to cells treated with purified particles resulted in significantly 
enhanced transfection efficiency (Boeckle et al., 2004). When NIH 3T3 cells were 
transfected with PEI and the Ensa siRNA at an N/P ratio of 20, no significant knockdown 
was achieved; it is possible that increasing the N/P ratio would achieve greater 
knockdown due to enhanced transfection efficiency facilitated by free PEI. However, the 
fluorescence microscopy experiments showed that when the cells were transfected with a 
complex of PEI and a FITC-labeled duplex at an N/P ratio of 20, the cells appeared 
unhealthy and showed signs of toxicity. Since an increased N/P ratio in polycation-
mediated transfection directly correlates with cellular toxicity (Godbey, Wu, & Mikos, 
2001; Morimoto et al., 2003), a desirable balance between increased transfection 
efficiency and reduced cytotoxicity must be maintained.  
This need for a balance between transfection efficiency and cytotoxicity also 
holds true for the delivery of the Ensa siRNA using HappyFect, in both NIH 3T3 cells 
and oocytes. While using 10 uL of HappyFect did not achieve much knockdown in NIH 
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3T3 cells at the transcript or protein level, 20 uL of HappyFect did achieve significant 
knockdown at the transcript level (Figure 9). However, 20 uL of HappyFect appeared to 
have toxic effects on the cells when the experiment was repeated. Before treating oocytes 
with HappyFect and the Ensa siRNA, I examined the toxicity of two different 
concentrations of transfection mixtures, containing 0.2 or 0.4% HappyFect in WB 
medium). In NIH 3T3 cells, 0.4 or 0.8% HappyFect solutions in serum-free DMEM were 
used for the transfections, with the 0.8% HappyFect solution having toxic effects on the 
cells when the experiment was repeated. However, although a 0.4% HappyFect solution 
did not seem to have toxic effects on NIH 3T3 cells, both 0.2 and 0.4% HappyFect 
solutions appeared to have toxic effects on the oocytes. It is possible that increasing the 
amount of HappyFect used for the oocyte experiments could improve the transfection 
efficiency of the Ensa siRNA. However, future cytotoxicity studies, such as the use of an 
MTT assay, may provide more information about achieving a balance between 
transfection efficiency and cytotoxicity.  
 
1.5. Efficiency of the Ensa siRNA 
RNAi is dependent on the effective delivery of shRNA or siRNA into cells as 
well as the ability of shRNA or siRNA to effectively associate with its complementary 
target mRNA and facilitate RNA degradation or translational arrest. While microinjection 
of the Ensa siRNA in mouse oocytes achieved a range of 39-91% knockdown in five 
experiments (Matthews & Evans, 2014), using Lipofectamine 2000 to deliver the Ensa 
siRNA cocktail into NIH 3T3 cells was only able to knock down Ensa mRNA levels by 
about 25-50%. While 100 pmoles, which was the amount of siRNA used for all 
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experiments, may not be sufficient for knockdown greater than 50%, it is also possible 
that the siRNA is not as efficient in the NIH 3T3 cells as it is in oocytes. For a better 
evaluation of the delivery potential of polycations, it might be beneficial to use a siRNA 
that is as efficient in the positive control cells that we are using (NIH 3T3) as in oocytes.   
 
2. Applications of an Alternative Nucleic Acid Delivery Vehicle in Oocytes 
 Although there are several considerations for polycation-mediated delivery of 
siRNA or shRNA into oocytes, the impact of an alternative method to microinjection 
would be tremendous for the field of oocyte biology. Particularly, developing a delivery 
vehicle to knock down targets that are important in oocyte maturation, such as ENSA, 
could have applications in non-hormonal contraception.  
ENSA, alpha-endosulfine, plays a regulatory role in meiosis. Mammalian oocytes 
progress through meiosis in a staggered fashion. Upon ovulation, oocytes undergo 
meiotic maturation, which is the progression from prophase I to metaphase of meiosis II. 
The exit from meiotic arrest, or re-entry into meiosis II is regulated by a collection of 
signaling proteins. Cyclin-dependent kinase 1 (CDK1) phosphorylates various substrates 
that stimulate events associated with re-entry into M-phase (Gharbi-Ayachi et al., 2010). 
Along with the phosphorylation of these substrates, the inhibition of protein phosphatase 
2A (PP2A) is essential for regulation of meiotic re-entry (Gharbi-Ayachi et al., 2010). 
ENSA is one protein that dephosphorylates PP2A and is therefore a key regulator of entry 
into meiosis (Gharbi-Ayachi et al., 2010).  Moreover, previous studies have identified 
physiological roles for ENSA in mouse and Drosophila oocytes. Endos mutant 
Drosophila oocytes and ENSA-deficient mouse oocytes both exhibit defects in 
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progression out of prophase I arrest (Matthews & Evans, 2014; Von Stetina et al., 2008). 
The essential role that ENSA plays in the regulation of meiosis in oocytes makes it a 
potential target for future non-hormonal contraceptive applications. Thus, developing a 
nanoparticle system that could circumvent microinjection and deliver gene disrupting 
agents into oocytes would not only transform mammalian oocyte research by elucidating 
unknown biological processes, but could also have long term implications for human 
contraception through the disruption of genes necessary for oocyte growth and 
maturation. 
3. Future Directions 
 The cytotoxicity of polycations is a major barrier in polycation-mediated 
transfections. Both HappyFect and PEI incurred cytotoxic effects on NIH 3T3 cells and 
oocytes. Although PEGylation is believed to reduce the cytotoxicity of PEI by providing 
a surface charge shield, it is possible that it may hinder the complex-forming behavior of 
PEI. Other measures have been developed to reduce the cytotoxicity of PEI. Acylation of 
the amino groups on the backbone of PEI has been shown to improve its transfection 
efficiency and reduce cytotoxicity (Aravindan, Bicknell, Brooks, Khutoryanskiy, & 
Williams, 2009; Thomas & Klibanov, 2002). The PEG that I used in this thesis was 
derivatized with a maleimide amine; it is possible that acylating amino groups of either 
the PEI or the amino groups of the PEG-maleimide-amine may reduce cytotoxicity.  
 Future experiments could also involve the investigation of other polycations to 
deliver nucleic acids into oocytes since PEI, PEGylated PEI, and HappyFect were not as 
effective in delivering the siRNA into NIH 3T3 cells as Lipofectamine. Along with PEI, 
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polyamidoamine (PAMAM) dendrimers are among the most extensively studied and 
widely used polycations. They are made of repetitively branched subunits of amide and 
amine functional groups. The relative low cost of synthesis of PAMAM dendrimers, 
along with their biocompatibility and structural control have made them candidates for 
applications in drug delivery (Kukowska-Latallo et al., 1996; Tomalia, Reyna, & 
Svenson, 2007). Unlike PEI, which is nondegradable, PAMAM dendrimers are 
biodegradable polymers with a backbone of polymer chains consisting of peptide bonds; 
as a result, they exhibit comparatively less cytotoxicity than PEI (Choi, Kang, Kim, Lim, 
& Chung, 2010).  
 Additionally, since cellular uptake is another potential barrier for introducing 
nucleic acids into oocytes, the incorporation of an oocyte-specific cell ligand into the 
transfection complex could enhance transfection. Particularly, combining a DNA or RNA 
aptamer that specifically binds to the zona pellucida of oocytes with a polycation delivery 
vehicle would allow us to introduce siRNA or shRNA into ZP-intact oocytes and could 








Moles of Phosphate (Constant) 6.1 x 10-11 
N/P Ratio Moles of 
Nitrogen 
Moles of PEI/PEG-PEI 
1 6.1 x 10-11 1.04 x 10-13 
5 3.05 x 10-10 5.2 x 10-13 
10 6.1 x 10-10 1.04 x 10-12 
15 9.15 x 10-10 1.57 x 10-12 
20 1.22 x 10-9 2.09 x 10-12 
 
 
Table 1. Molar amounts of PEI or PEGylated PEI used for gel mobility shift experiments 
with pGEM-3Z plasmid. 20 ng of plasmid DNA (61 pmoles of phosphate) were 














Moles of Phosphate (Constant) 1.8 x 10-10 





5 9 x 10-10 1.54 x 10-12 
10 1.8 x 10-9 3.09 x 10-12 
15 2.7 x 10-9 4.63 x 10-12 
20 3.6x 10-9 6.17 x 10-12 
25 4.5 x 10-9 7.72 x 10-12 
30 5.4 x 10-9 9.26 x 10-12 
35 6.3 x 10-9 1.08 x 10-12 
40 7.2 x 10-9 1.23 x 10-12 
 
Table 2. Molar amounts of PEI or PEGylated PEI used for gel mobility shift experiments 
with RNA duplex containing a FITC labeled oligo-2’-O-methylribonucleotide annealed 
to a complementary RNA. 5 pmoles of the duplex (180 pmoles of phosphate) were 
















Table 3. Ensa mRNA sequences targeted by the Ensa ON-TARGETplus SMARTpool 


























24-well 500 µL 25  10  2 
12-well 1 mL 50  20  4 
6-well 2.5 mL 125  50  10 
60-mm 5 mL 250  100  20 
 
Table 4. Suggested volumes and amounts of reagents for transfections using HappyFect 
(Tecrea Ltd). According to manufacturer’s instructions, amounts of siRNA and 
HappyFect can be varied +/- 50%. For transfections in NIH 3T3 cells the 6-well plate 
format was used, with 10 or 20 µL of HappyFect. Suggested amounts for the 24-well 
plate format were used for treatment of oocytes with HappyFect, with 1 µL of HappyFect 
































Table 5. Primer sequences used for RT-qPCR experiments evaluating levels of Ensa 






















Figure 1. Chemical structures of a few representative polycations used for nucleic acid 
delivery (Thomas & Klibanov, 2003). Branched polyethyleneimine, explored in this 
thesis, is one of the most effective delivery agents due to its ability to act as a proton 
















Figure 2. Schematic of the synthesis of PEGylated PEI. Conjugation of PEG to PEI 
involves 3 steps. Step 1 is the addition of an SATP linker to form an acetylated PEI 
molecule with a protected sulfhydryl group. Step 2 is the deacetylation of the PEI 
molecule using hydroxylamine hydrochloride in order to free the thiol group. Step 3 
involves the selective reaction between the free thiol group attached to PEI with the 
maleimide group of the PEG derivative used in this project.  The molar ratio of PEG to 



















































Figure 3. Graph of the size of particles of a solution of unmodified PEI or PEGylated 
PEI, as determined by dynamic light scattering.  The y-axis shows the average 
hydrodynamic radius of 5 measurements (5 different aliquots of one solution). The 




















Figure 4. 0.8% agarose gels, containing SYBR green dye, loaded with solutions of 
pGEM-3Z and PEI or PEGylated PEI at varying N/P ratios. Each lane is loaded with a 
mixture of plasmid and polycation with a different N/P ratio (see Table 1 for specific 
molar amounts). An N/P ratio of 0 indicates that only the plasmid (without the 
polycation) was loaded. Disappearance of the SYBR green signal signifies complex 

















Figure 5. A) A 20% native polyacrylamide gel loaded with a FITC labeled oligo-2’-O-
methylribonucleotide alone (FITC-Oligo) or the oligo annealed to a complementary RNA 
(FITC-Duplex). B) 1% agarose gels loaded with solutions of the FITC-duplex and PEI or 
PEGylated PEI at varying N/P ratios. Each lane is loaded with a mixture of the duplex 
and a polycation with a different N/P ratio (see table 2 for specific molar amounts). An 
N/P ratio of 0 indicates that only the duplex (without the polycation) was loaded. 





























y = -3.2774x + 36.143
R² = 0.9998
































Efficiency  of Gapdh Primer Set = (-1 + 10
(-1/-3.2774)
) * 100 
= 101.9% 
Efficiency of Ensa Primer Set = (-1 + 10
(-1/-3.1775
)) * 100 = 
106.5 % 
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Figure 6.  Standard curve for Gapdh and Ensa primers generated by preparing serial 
dilutions of cDNA from NIH 3T3 cells. Cycle threshold is on the y-axis and the log of the  
template concentration (set as fg; estimated from RNA input) is on the x-axis. Slope of 





























Figure 7. A) Levels of Ensa transcript in NIH 3T3 cells, 44-48 hours following a 
transfection using Lipofectamine as a delivery vehicle. The graph shows relative Ensa 
mRNA levels of cells transfected with a complex of Lipofectamine and Ensa siRNA 
(Ensa siRNA on x-axis) or Lipofectamine alone (control on x-axis). Relative Ensa 
mRNA levels are normalized to a reference gene, Gapdh. Error bars represent a pooled 
standard error of the variation in Ct values between triplicates for each primer set, as well 
as the variation between each experimental group (control and Ensa siRNA).  B) Levels 
of ENSA protein in NIH 3T3 cells, 44-48 hours following a transfection using 
Lipofectamine as a delivery vehicle. Western blots using cell lysate from control cells 
(Lipofectamine only) or Ensa siRNA treated cells (Lipofectamine + Ensa siRNA were 
prepared by probing for ENSA (top) and Actin (bottom) separately.  Each blot shows 
protein bands for different amounts of cell lysate for each experimental group. The 
numbers above each blot represent the volume of cell lysate (µL) loaded in each well of 
the polyacrylamide gel. To stay within linear range, ENSA protein levels in 0.5 µL of cell 
















Figure 8. A) Levels of Ensa transcript in NIH 3T3 cells, 44-48 hours following a 
transfection using PEI or PEGylated PEI as a delivery vehicle. The graph shows relative 
Ensa mRNA levels of cells transfected with a complex of PEI, PEGylated PEI, or 
Lipofectamine and Ensa siRNA (Ensa siRNA on x-axis) or PEI, PEGylated PEI, or 
Lipofectamine alone (control on x-axis). Complex of Ensa siRNA and polycations is 
formed at an N/P ratio of 10.  B) Graph of relative Ensa mRNA levels of cells transfected 
with PEI or Lipofectamine and Ensa siRNA, or PEI or Lipofectamine alone; complexes 
of Ensa siRNA and PEI are formed at an N/P ratio of 20. For both experiments (A & B), 
Lipofectamine is used as a positive control. Relative Ensa mRNA levels are normalized 
to a reference gene, Gapdh. Error bars represent a pooled standard error of the variation 
in Ct values between triplicates for each primer set, as well as the variation between each 
















Figure 9. A) Levels of Ensa transcript in NIH 3T3 cells, 44-48 hours following a 
transfection using HappyFect as a delivery vehicle. The graph shows relative Ensa 
mRNA levels of cells transfected with a complex of HappyFect or Lipofectamine and 
Ensa siRNA (Ensa siRNA on x-axis) or HappyFect or Lipofectamine alone (control on x-
axis). 10 µL of HappyFect is used. B) Transcript levels of Ensa in NIH 3T3 cells, 44-48 
hours following a transfection using 5 µL of HappyFect. For both experiments (A & B), 
Lipofectamine is used as a positive control. Relative Ensa mRNA levels are normalized 
to a reference gene, Gapdh. Error bars represent a pooled standard error of the variation 
in Ct values between triplicates for each primer set, as well as the variation between each 
experimental group (control and Ensa siRNA).  C) Levels of ENSA protein in NIH 3T3 
cells, 44-48 hours following a transfection using 10 µL of HappyFect as a delivery 
vehicle. Western blots using cell lysate from control cells (HappyFect only) or Ensa 
siRNA treated cells (HappyFect + Ensa siRNA) were prepared by probing for ENSA 
(top) and GAPDH (bottom) separately.  Each blot shows protein bands for different 
amounts of cell lysate for each experimental group. The numbers above each blot 
represent the volume of cell lysate (µL) loaded in each well of the polyacrylamide gel. 
For knockdown calculations, ENSA protein levels were normalized to GAPDH levels in 

















Lipofectamine  PEI (N/P 20) 
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Figure 10.   Uptake of the FITC labeled duplex using Lipofectamine or PEI as a delivery 
vehicle. NIH 3T3 cells were transfected with a complex of Lipofectamine and the FITC-
duplex or a complex of PEI and the FITC-duplex. A complex of the duplex and PEI was 
formed at an N/P ratio of 20. Live cells were imaged on a Zeiss Axio Observer Z1. 
Images were taken with 10X resolution using differential interference contrast (DIC). 
Top two images are taken using transillumination (without the GFP filter). Bottom two 









































Figure 11.  Levels of ENSA protein in oocytes, 44-48 hours following treatment with 
HappyFect. Western blots using 20 control oocytes (HappyFect + Negative control 
siRNA) and 20 Ensa siRNA oocytes (HappyFect + Ensa siRNA) were prepared by 
probing for ENSA (top) and GAPDH (bottom) separately.  To quantify knockdown, 
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Design of a novel oocyte-specific gene delivery mechanism to inhibit expression of alpha endosulfine 
(ENSA)   
 Utilizing quantitative RT-PCR and fluorescence microscopy to examine si-RNA 
 mediated knockdown of ENSA in murine cells 
 Synthesizing a polymer-based nanoparticle system  
 Applying gel electrophoresis, size-exclusion chromatography, and dynamic light 
scattering methods to characterize the nanoparticle system 
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Investigation of the function of Poly ADP Ribose Polymerases (PARPs)  
 Constructed a cDNA library of 17 PARP proteins using advanced molecular cloning 
techniques for application in future studies identifying the relationship between  
PARPs and miRNA-155 











Center for Inherited Disease Research, Baltimore, MD          2011-2012 
Research Technologist, Principal Investigator: Dr. Kim Doheny 
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